Breckenridge Pharmaceutical, Inc. and Impopharma, Inc. enter into licensing agreement

Friday, September 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOCA RATON, Fla., Sept. 29, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered

into a licensing agreement with Impopharma, Inc. to commercialize a generic version of a leading corticosteroid product with generic sales in excess of $25M.  Impopharma is the manufacturer of the ANDA, which will be marketed
exclusively by Breckenridge for the U.S. market. The product ANDA has been filed and is pending final approval by the U.S. Food and Drug Administration.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com

About Impopharma

Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, dermal products. Please visit www.impopharma.com.

View original content:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-inc-and-impopharma-inc-enter-into-licensing-agreement-300528326.html

SOURCE Breckenridge Pharmaceutical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store